BioVentrix, a firm in San Ramon, California, is bringing to Europe its Revivent Myocardial Anchoring System which just received CE Mark approval. The system is used to perform the Less Invasive Ventricular Enhancement (LIVE) procedure, a method of reshaping the ventricle to exclude damaged heart tissue so that healthy tissue is all that’s surrounding the ventricular chamber.
The procedure does not require the patient to be put on bypass, nor are there any incisions into the heart. Because everything is done in a much less invasive manner as opposed to traditional ventricular restoration, patients that would otherwise be ineligible for surgery may benefit from the procedure.
From the announcement, and check out the video below demonstrating the procedure:
The Revivent™ Myocardial Anchoring System addresses the safety concerns of physicians about subjecting patients to invasive surgical interventions on the heart’s left ventricle. Made possible by the Revivent system, the LIVE™ procedure can be performed as a separate stand-alone procedure, concurrent with other procedures (e.g., CABG) or during other occasions when a sternotomy is already employed. Neither a myocardial incision nor cardiopulmonary bypass is required. Additionally, the Revivent system is deployed using a straightforward, epicardial approach that can be completed in about one hour.
Less Invasive Ventricular Enhancement™ (LIVE™) therapy is an innovative, new off-pump (i.e., beating heart) procedure that helps restore the left ventricle’s intrinsic functional efficiency, rather than relying on a surrogate pumping device or other invasive treatment. The only therapy currently designed to restore optimal left ventricle size and function, LIVE provides physician teams with a gentler surgical option that enables them to more confidently treat heart failure patients who may not tolerate left ventricle incisions.